Is There a Role for Clozapine in the Treatment of Children and Adolescents?

Autor/inn/en	Findling, Robert L.; Frazier, Jean A.; Gerbino-Rosen, Ginny; Kranzler, Harvey N.; Kumra, Sanjiv; Kratochvil, Christopher J.
Titel	Is There a Role for Clozapine in the Treatment of Children and Adolescents?
Quelle	In: Journal of the American Academy of Child & Adolescent Psychiatry, 46 (2007) 3, S.423 (6 Seiten) PDF als Volltext Verfügbarkeit
Sprache	englisch
Dokumenttyp	gedruckt; online; Zeitschriftenaufsatz
ISSN	0890-8567
Schlagwörter	Stellungnahme; Patients; Adolescents; Schizophrenia; Pediatrics; Drug Therapy; Children; Mental Disorders; Symptoms (Individual Disorders); Developmental Stages; Outcomes of Treatment + Suchen Sie Ihr Suchwort? Patient; Adolescent; Adolescence; Adoleszenz; Jugend; Jugendalter; Jugendlicher; Schizophrenie; Klinische Sozialpädiatrie; Child; Kind; Kinder; Mental illness; Geisteskrankheit; Psychiatrische Symptomatik
Abstract	This article presents responses to the question of whether clozapine is ever appropriate to use in the pediatric population. Among others, Jean A. Frazier also agreed that clozapine is appropriate for use in the pediatric population. Clozapine has truly revolutionized the treatment of refractory patients with schizophrenia at any age. This agent was approved by the U.S. Food and Drug Administration (FDA) in 1989 for use in individuals ages 18 years or older with treatment refractory schizophrenia. Subsequent to clozapine, the FDA has approved a number of atypical antipsychotics for the treatment of psychotic disorders, but none to date are approved for use in children and adolescents. Despite the superior efficacy of clozapine, its use has been limited because of its complex side effect profile, consisting of hypersalivation, weight gain, metabolic abnormalities, cardiovascular side effects, sedation, seizures, and agranulocytosis. Children may be more prone to developing these side effects than adults because of developmental differences in the metabolism of this agent. (ERIC).
Anmerkungen	Lippincott Williams & Wilkins. P.O. Box 1600, Hagerstown, MD 21741. Tel: 800-638-3030; Tel: 301-223-2300; Fax: 301-223-2400; Web site: http://www.lww.com/product/?0890-8567
Erfasst von	ERIC (Education Resources Information Center), Washington, DC
Update	2017/4/10